Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)

NCT07631325 is registered in ClinicalTrials.gov with John Kirkwood as lead sponsor.

NCT NCT07631325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07631325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of MOR Antagonism With Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma (MORALE-MM)
Lead sponsor
John Kirkwood
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2030
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable cutaneous melanoma